Inhibition of intracellular proliferation of Leishmania parasites in vitro and suppression of skin lesion development in BALB/c mice by a novel lipid A analog (ONO-4007)

American Journal of Tropical Medicine and Hygiene

Volumn 67, Issue 2 SUPPL., 2002, Pages 184-190

  Khan, Mohammed A K ^a   Maruno, Motoyoshi ^a   Khaskhely, Noor M ^a   Ramzi, Saeef T ^a   Hosokawa, Atsushi ^a   Uezato, Hiroshi ^a   Gomez Landires, Eduardo A ^a   Hashiguchi, Yoshihisa ^a   Nonaka, Shigeo ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 DEOXY 3 O (9 PHENYLNONANOYL) 2 [3 (9 PHENYLNONANOYLOXY)TETRADECANOYLAMINO]GLUCOPYRANOSE 4 SULFATE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA; LEISHMANIASIS; MACROPHAGE; MOUSE; NONHUMAN; PROMASTIGOTE;

ANIMALIA; LEISHMANIA AMAZONENSIS; LEISHMANIA MAJOR; PROTOZOA;

EID: 0036697753     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2002.67.184     Document Type: Article

References (36)

1. Report of a WHO expert committee, 1990. Control of the leishmaniases. World Health Organ Tech Rep Ser 793: 1-158.
2. Ashford RW, Desjeux P, DeRaadt P, 1992. Estimation of population at risk of infection and number of cases of leishmaniasis. Parasitol Today 8: 104-105.
3. Ollario PL, Bryceson ADM, 1993. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today 9: 323-328.
4. Koff AB, Rosen T, 1994. Treatment of cutaneous leishmaniasis. J Am Acad Dermatol 31: 693-708.
5. Lainson R, Shaw JJ, 1987. Evolution, Classification and Geographical Distribution of Leishmania. Peters W, Killick-Kendrick R, eds. The Leishmaniases in Biology and Medicine. Volume 1. London: Academic Press, 1-120.
6. Matsumoto N, Oida H, Aze Y, Akimoto A, Fujita T, 1998. Intratumoral tumor necrosis factor induction and tumor growth suppression by ONO-4007, a low toxicity lipid A analog. Anticancer Res 18: 4283-4289.
7. Morrison DC, Ryan JL, 1979. Bacterial endotoxins and host immune responses. Adv Immunol 28: 293-450.
8. Somlyo B, Csanky E, Shi XM, Zhang YL, Kovats E, Bona-Liptak E, Nowotony AM, di Tripo D, 1992. Molecular requirement of endotoxin (ET) actions: changes in the immune adjuvant, TNF liberating and toxic properties of endotoxin during alkaline hydrolysis. Int J Immunopharmacol 14: 131-142.
9. Kuramitsu Y, Nishibe M, Ohiro Y, Matsushita K, Yuan L, Obara M, Kobayashi M, Hosokawa M, 1997. A new synthetic lipid a analog, ONO-4007, stimulates the production of tumor necrosis factor-alpha in tumor tissues, resulting in the rejection of transplanted rat hepatoma cells. Anticancer Drugs 8: 500-508.
10. Yang D, Satoh M, Ueda H, Tsukagoshi S, Yamazaki M, 1994. Activation of tumor infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects. Cancer Immunol Immunother 38: 287-293.
11. Mastumoto N, Aze Y, Akimoto A, Fujita T, 1998. ONO-4007, an antitumor lipid A analog, induces tumor necrosis factor-α production by human monocytes only under primed state: different effects of ONO-4007 and lipoploysaccharide on cytokine production. J Pharmacol Exp Ther 284: 189-195.
12. Hattori Y, Szabo C, Gross S, Thiemermann C, Vane JR, 1995. Lipid A and the lipid A analogue anti-tumour compound ONO-4007 induce nitric oxide synthase in vitro and in vivo. Eur J Pharmacol 291: 83-90.
13. Hibbs JB Jr, Vavrin Z, Taintor RR, 1987. L-arginine is required for expression of the activated macrophage effector mechanism carrying selective metabolic inhibition in target cells. J Immunol 138: 550-565.
14. Bogdan C, Moll H, Solbach W, Röllinghoff M, 1990. Tumor necrosis factor-alpha in combination with interferon-gamma but not with interleukin-4 activates murine macrophages for elimination of Leishmania major amastigotes. Eur J Immunol 20: 1131-1135.
15. Liew FY, Li Y, Millott S, 1990. Tumor necrosis factor-α synergies with IFN-α in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 145: 4306-4310.
16. Green SJ, Crawford RM, Hockmeyer JT, Meltzer MS, Nacy CA, 1990. Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-γ stimulated macrophages by induction of tissue necrosis factor-alpha. J Immunol 145: 4290-4297.
17. r congenic mouse starins. Infect Immun 59: 3935-3944.
18. Titus RG, Sherry B, Cerami A, 1989. Tumor necrosis factor plays a protective role experimental murine cutaneous leishmaniasis. J Exp Med 170: 2097-2104.
19. Liew FY, Parkinson C, Millot S, Severn A, Carrier M, 1990. Tumor necrosis factor (TNF-α) in leishmaniasis. I. TNF-α mediates host protection against cutaneous leishmaniasis. Immunology 69: 570-573.
20. Cunha FQ, Weiser WY, David JR, Moss DW, Moncada S, Liew FY, 1993. Recombinant migration inhibitory factor induces nitric oxide synthase in murine macrophages. J Immunol 150: 1908-1912.
21. Hibbs JB Jr, Taintor RR, Vavrin Z, Granger DL, Drapier JC, Amber IJ, Lancaster JR Jr, 1990. Synthesis of nitric oxide from a terminal guanidino atom of L-arginine: a molecular mechanism regulating cellular proliferation that targets intracellular iron. Moncada S, Higgs EA, eds. Nitric Oxide From L-arginine: A Bio-Regulatory System. Amsterdam: Elsevier Publishers: 189-223.
22. Moncada S, Palmer RM, Higgs EA, 1989. Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol 38: 1709-1715.
23. Reed SG, Scott P, 1993. T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol 5: 524-531.
24. Locksley RM, Scott P, 1991. Helper T-cell subsets in murine leishmaniasis: induction, expansion, and effector function. Immunol Today 12: A58-61.
25. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A, 1988. Immunoregulation of cutaneous leishmaniasis: T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 168: 1675-1684.
26. + lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci USA 88: 7011-7015.
27. Talmadge JE, Tribble HR, Pennington RW, Phillips H, Wiltrout RH, 1987. Immunomodulatory and immunotherapeutic properties of recombinant γ-interferon and recombinant tumor necrosis factor in mice. Cancer Res 47: 2563-2570.
28. Murray HW, 1990. Gamma interferon, cytokine-induced macrophage activation, and antimicrobial host defense: in vitro, in animals and humans. Diagn Microbiol Infect Dis 13: 411-421.
29. Veress B, Abdalla RE, El Hassan AM, 1981. Electron microscopic investigations on leishmaniasis in the Sudan: II. Ultrastructural morphology of macrophage-parasite interaction in human and hamster macrophages in vivo. Ann Trop Med Parasitol 75: 607-613.
30. Green SJ, Meltzer MS, Hibbs JB Jr, Nacy CA, 1990. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol 144: 278-283.
31. Liew FY, Millot S, Parkinson C, Palmer RMJ, Moncada S, 1990. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 144: 4794-4797.
32. Iyengar R, Stuehr DJ, Marletta MA, 1987. Macrophage synthesis of nitrite, nitrate and N-nitrosamines: precursors and role of the respiratory burst. Proc Natl Acad Sci USA 84: 6369-6373.
33. Palmer RMJ, Ashton DS, Moncada S, 1988. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333: 664-666.
34. Ding AH, Nathan CF, Stuehr DJ, 1988. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 141: 2407-2412.
35. Drapier JC, Wietzerbin J, Hibbs JB Jr, 1988. Interferon-gamma and tumor necrosis factor induce the L-arginine dependent cytotoxic effector mechanism in murine macrophages. Eur J Immunol 18: 1587-1592.
36. Mauel J, Ransijn A, Buchmuller-Rouiller Y, 1991. Killing of Leishmania parasites in activated murine macrophages is based on an L-arginine-dependent process that produces nitrogen derivatives. J Leukoc Biol 49: 73-82.